NCT01972763View on ClinicalTrials.gov

Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
Recalcitrant Wet Age-related Macular Degeneration
Interventions
DRUG

Ranibizumab

Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.

Trial Locations (1)

94040

Northern California Retina Vitreous Associates, Mountain View

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Northern California Retina Vitreous Associates

OTHER